GlassScriptPhysician profile
Min Chong Yoo
NPI 1962606756
$2,497.47
in general payments reported to CMS, 2019-2025
27 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $624 · 2023: $1,217 · 2024: $357 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Travel and Lodging: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.48 |
| Travel and Lodging | $769.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,086.77 | 2023 | 1688, Spy-Phi System, 1788 |
| Hologic INC | $565.88 | 2022 | |
| Merck Sharp & Dohme LLC | $204.12 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Viiv Healthcare Company | $116.45 | 2024 | Dovato |
| Daiichi Sankyo INC. | $62.92 | 2024-2025 | Enhertu |
| Puma Biotechnology, INC. | $45.87 | 2023-2025 | |
| Menarini Silicon Biosystems, INC. | $36.06 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.73 | 2022-2024 | Gattex |
| Blueprint Medicines Corporation | $29.09 | 2022-2024 | Ayvakit |
| Medtronic, INC. | $28.84 | 2022 | |
| Tersera Therapeutics LLC | $27.49 | 2023 | Zoladex |
| Pharmaand Gmbh | $27.43 | 2025 | Rubraca |
| Tolmar, INC. | $26.47 | 2025 | Rubraca, Eligard |
| Urogen Pharma, INC. | $20.91 | 2025 | |
| Spectrum Pharmaceuticals INC. | $18.24 | 2025 | Rolvedon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.68 | 2024 | |
| Stemline Therapeutics INC. | $15.45 | 2025 | Orserdu |
| Taiho Oncology, INC. | $14.70 | 2024 | |
| Hologic Sales and Service, LLC | $14.61 | 2023 | Localizer |
| Adc Therapeutics America, INC. | $14.25 | 2024 | |
| Genmab U.S., INC. | $13.70 | 2023 | Epkinly |
| Pfizer INC. | $13.68 | 2025 | |
| Springworks Therapeutics, INC. | $13.56 | 2024 | Ogsiveo |
| Janssen Biotech, INC. | $13.53 | 2024 | Tecvayli, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $13.15 | 2024 | |
| Iovance Biotherapeutics, INC. | $13.04 | 2025 | Amtagvi |
| Seagen INC. | $12.85 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.